A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)
This study is ongoing, but not recruiting participants.
First Posted: October 10, 2011
Last Update Posted: June 21, 2017
Information provided by (Responsible Party):